Research
Hormonal
Semaglutide 2.4 mg shows significant treatment interactions based on the presence of type 2 diabetes and dyslipidemia at baseline compared to placebo.
Healthcare providers should assess comorbidities when evaluating the potential effectiveness of semaglutide.
StrongSupportsmedium confidence
Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).
Why this rating
Based on the randomized controlled trial design of STEP 6.
Source
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis
Takashi Kadowaki et al. · Obesity Research & Clinical Practice · 2024
rct · n=401Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →